Tom 9, Nr 3 (2024)
Wytyczne / stanowisko ekspertów
Opublikowany online: 2024-11-15
Wyświetlenia strony 438
Wyświetlenia/pobrania artykułu 149
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Rekomendacje Polskiego Towarzystwa Ginekologów i Położników: spektrum łożyska wrastającego (PAS) — diagnostyka prenatalna i postępowanie

Hubert Huras1, Wojciech Cnota2, Krzysztof Czajkowski3, Mariusz Grzesiak45, Andrzej Jaworowski1, Piotr Kaczmarek6, Sebastian Kwiatkowski7, Bożena Leszczyńska-Gorzelak8, Ewa Wender-Ożegowska9, Mirosław Wielgoś1011, Dariusz Wydra12, Mariusz Zimmer13, Piotr Sieroszewski14
Ginekologia i Perinatologia Praktyczna 2024;9(3):192-213.

Streszczenie

Brak

Artykuł dostępny w formacie PDF

Dodaj do koszyka: 49,00 PLN

Posiadasz dostęp do tego artykułu?

Referencje

  1. Morlando M, Collins S. Placenta Accreta Spectrum Disorders: Challenges, Risks, and Management Strategies. Int J Womens Health. 2020; 12: 1033–1045.
  2. Bartels HC, Postle JD, Downey P, et al. Placenta Accreta Spectrum: A Review of Pathology, Molecular Biology, and Biomarkers. Dis Markers. 2018; 2018: 1507674.
  3. Jauniaux E, Chantraine F, Silver RM, et al. FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on placenta accreta spectrum disorders: Epidemiology. Int J Gynaecol Obstet. 2018; 140(3): 265–273.
  4. Jauniaux E, Bunce C, Grønbeck L, et al. Prevalence and main outcomes of placenta accreta spectrum: a systematic review and meta-analysis. Am J Obstet Gynecol. 2019; 221(3): 208–218.
  5. Committee Opinion No. 529. Obstetrics & Gynecology. 2012; 120(1): 207–211.
  6. Morlando M, Schwickert A, Stefanovic V, et al. International Society for Placenta Accreta Spectrum (IS-PAS). Maternal and neonatal outcomes in planned versus emergency cesarean delivery for placenta accreta spectrum: A multinational database study. Acta Obstet Gynecol Scand. 2021; 100 Suppl 1: 41–49.
  7. American College of Obstetricians and Gynecologists, Society for Maternal-Fetal Medicine. Obstetric Care Consensus No. 7: Placenta Accreta Spectrum. Obstet Gynecol. 2018; 132(6): e259–e275.
  8. Eller AG, Porter TF, Soisson P, et al. Optimal management strategies for placenta accreta. BJOG. 2009; 116(5): 648–654.
  9. Bartels HC, Terlizzi K, Cooney N, et al. Quality of life and sexual function after a pregnancy complicated by placenta accreta spectrum. Aust N Z J Obstet Gynaecol. 2021; 61(5): 708–714.
  10. Grover B, Einerson BD, Keenan KD, et al. Patient-Reported Health Outcomes and Quality of Life after Peripartum Hysterectomy for Placenta Accreta Spectrum. Am J Perinatol. 2022; 39(3): 281–287.
  11. Tol ID, Yousif M, Collins SL. Post traumatic stress disorder (PTSD): The psychological sequelae of abnormally invasive placenta (AIP). Placenta. 2019; 81: 42–45.
  12. Collins SL, Alemdar B, van Beekhuizen HJ, et al. International Society for Abnormally Invasive Placenta (IS-AIP). Evidence-based guidelines for the management of abnormally invasive placenta: recommendations from the International Society for Abnormally Invasive Placenta. Am J Obstet Gynecol. 2019; 220(6): 511–526.
  13. Einerson BD, Gilner JB, Zuckerwise LC. Placenta Accreta Spectrum. Obstet Gynecol. 2023; 142(1): 31–50.
  14. Cnota W, Banas E, Dziechcinska-Poletek D, et al. "The Killer Placenta" - a threat to the lives of young women giving birth by cesarean section. Ginekol Pol. 2022; 93(4): 314–320.
  15. Wu S, Kocherginsky M, Hibbard JU. Abnormal placentation: twenty-year analysis. Am J Obstet Gynecol. 2005; 192(5): 1458–1461.
  16. Mogos MF, Salemi JL, Ashley M, et al. Recent trends in placenta accreta in the United States and its impact on maternal-fetal morbidity and healthcare-associated costs, 1998-2011. J Matern Fetal Neonatal Med. 2016; 29(7): 1077–1082.
  17. Luke RK, Sharpe JW, Greene RR. Placenta accreta: the adherent or invasive placenta. Am J Obstet Gynecol. 1966; 95(5): 660–668.
  18. Tantbirojn P, Crum CP, Parast MM. Pathophysiology of placenta creta: the role of decidua and extravillous trophoblast. Placenta. 2008; 29(7): 639–645.
  19. Jauniaux E, Hussein AM, Elbarmelgy RM, et al. Failure of placental detachment in accreta placentation is associated with excessive fibrinoid deposition at the utero-placental interface. Am J Obstet Gynecol. 2022; 226(2): 243.e1–243.e10.
  20. Jauniaux E, Jurkovic D. Placenta accreta: pathogenesis of a 20th century iatrogenic uterine disease. Placenta. 2012; 33(4): 244–251.
  21. Silver RM, Landon MB, Rouse DJ, et al. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Maternal morbidity associated with multiple repeat cesarean deliveries. Obstet Gynecol. 2006; 107(6): 1226–1232.
  22. Timor-Tritsch IE, Monteagudo A, Cali G, et al. Cesarean scar pregnancy and early placenta accreta share common histology. Ultrasound Obstet Gynecol. 2014; 43(4): 383–395.
  23. Thurn L, Lindqvist PG, Jakobsson M, et al. Abnormally invasive placenta-prevalence, risk factors and antenatal suspicion: results from a large population-based pregnancy cohort study in the Nordic countries. BJOG. 2016; 123(8): 1348–1355.
  24. Jauniaux E, Ayres-de-Campos D. FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on placenta accreta spectrum disorders: Introduction. Int J Gynaecol Obstet. 2018; 140(3): 261–264.
  25. Badr DA, Al Hassan J, Salem Wehbe G, et al. Uterine body placenta accreta spectrum: A detailed literature review. Placenta. 2020; 95: 44–52.
  26. Miller HE, Leonard SA, Fox KA, et al. Placenta Accreta Spectrum Among Women With Twin Gestations. Obstet Gynecol. 2021; 137(1): 132–138.
  27. Modest AM, Toth TL, Johnson KM, et al. Placenta Accreta Spectrum: In Vitro Fertilization and Non-In Vitro Fertilization and Placenta Accreta Spectrum in a Massachusetts Cohort. Am J Perinatol. 2021; 38(14): 1533–1539.
  28. Türker Aras ÜA, Korkmazer E, Üstünyurt E. The nightmare of obstetricians - the placenta accreta spectrum in primiparous pregnant women. Ginekol Pol. 2023; 94(2): 135–140.
  29. Jauniaux E, Alfirevic Z, Bhide AG, et al. Royal College of Obstetricians and Gynaecologists. Placenta Praevia and Placenta Accreta: Diagnosis and Management: Green-top Guideline No. 27a. BJOG. 2019; 126(1): e1–e48.
  30. Jauniaux E, Collins S, Burton GJ. Placenta accreta spectrum: pathophysiology and evidence-based anatomy for prenatal ultrasound imaging. Am J Obstet Gynecol. 2018; 218(1): 75–87.
  31. Jauniaux E, Hecht JL, Elbarmelgy RA, et al. Searching for placenta percreta: a prospective cohort and systematic review of case reports. Am J Obstet Gynecol. 2022; 226(6): 837.e1–837.e13.
  32. Einerson B, Comstock J, Silver R, et al. Placenta Accreta Spectrum Disorder. Obstetrics & Gynecology. 2020; 135(5): 1104–1111.
  33. Jauniaux E, Ayres-de-Campos D, Langhoff-Roos J, et al. FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO classification for the clinical diagnosis of placenta accreta spectrum disorders. Int J Gynaecol Obstet. 2019; 146(1): 20–24.
  34. Hecht JL, Baergen R, Ernst LM, et al. Classification and reporting guidelines for the pathology diagnosis of placenta accreta spectrum (PAS) disorders: recommendations from an expert panel. Mod Pathol. 2020; 33(12): 2382–2396.
  35. Silver RM, Fox KA, Barton JR, et al. Center of excellence for placenta accreta. Am J Obstet Gynecol. 2015; 212(5): 561–568.
  36. Eller AG, Bennett MA, Sharshiner M, et al. Maternal morbidity in cases of placenta accreta managed by a multidisciplinary care team compared with standard obstetric care. Obstet Gynecol. 2011; 117(2 Pt 1): 331–337.
  37. Afshar Y, Dong J, Zhao P, et al. Circulating trophoblast cell clusters for early detection of placenta accreta spectrum disorders. Nat Commun. 2021; 12(1): 4408.
  38. Shainker SA, Silver RM, Modest AM, et al. Placenta accreta spectrum: biomarker discovery using plasma proteomics. Am J Obstet Gynecol. 2020; 223(3): 433.e1–433.e14.
  39. Conturie CL, Lyell DJ. Prenatal diagnosis of placenta accreta spectrum. Curr Opin Obstet Gynecol. 2022; 34(2): 90–99.
  40. Timor-Tritsch IE, Monteagudo A. Unforeseen consequences of the increasing rate of cesarean deliveries: early placenta accreta and cesarean scar pregnancy. A review. Am J Obstet Gynecol. 2012; 207(1): 14–29.
  41. Zimmer M, Sieroszewski P, Wielgoś M, et al. Algorytm postępowania w przypadkach łożyska przodującego i/lub łożyska z nieprawidłową implantacją (PAS). Polskie Towarzystwo Ginekologów i Położników — 2022, cz. I i II. Ginekologia i Perinatologia Praktyczna. 2022; 7: 92–95.
  42. Miller R, Gyamfi-Bannerman C. Society for Maternal-Fetal Medicine (SMFM), Publications Committee. Electronic address: pubs@smfm.org. Society for Maternal-Fetal Medicine Consult Series #63: Cesarean scar ectopic pregnancy. Am J Obstet Gynecol. 2022; 227(3): B9–BB20.
  43. Collins SL, Ashcroft A, Braun T, et al. European Working Group on Abnormally Invasive Placenta (EW-AIP). Proposal for standardized ultrasound descriptors of abnormally invasive placenta (AIP). Ultrasound Obstet Gynecol. 2016; 47(3): 271–275.
  44. Jauniaux E, Bhide A, Kennedy A, et al. FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on placenta accreta spectrum disorders: Prenatal diagnosis and screening. Int J Gynaecol Obstet. 2018; 140(3): 274–280.
  45. Hessami K, Salmanian B, Einerson BD, et al. Clinical Correlates of Placenta Accreta Spectrum Disorder Depending on the Presence or Absence of Placenta Previa: A Systematic Review and Meta-analysis. Obstet Gynecol. 2022; 140(4): 599–606.
  46. Jauniaux E, D'Antonio F, Bhide A, et al. Delphi consensus expert panel. Modified Delphi study of ultrasound signs associated with placenta accreta spectrum. Ultrasound Obstet Gynecol. 2023; 61(4): 518–525.
  47. Sargent W, Gerry S, Collins SL. A Risk-Prediction Model for Placenta Accreta Spectrum Severity From Standardized Ultrasound Markers. Ultrasound Med Biol. 2023; 49(2): 512–519.
  48. Happe SK, Yule CS, Spong CY, et al. Predicting Placenta Accreta Spectrum: Validation of the Placenta Accreta Index. J Ultrasound Med. 2021; 40(8): 1523–1532.
  49. Kolak M, Gerry S, Huras H, et al. IS‐PAS group. External validation of and improvement upon a model for the prediction of placenta accreta spectrum severity using prospectively collected multicenter ultrasound data. Acta Obstet Gynecol Scand. 2024 [Epub ahead of print].
  50. De Oliveira Carniello M, Oliveira Brito LG, Sarian LO, et al. Diagnosis of placenta accreta spectrum in high-risk women using ultrasonography or magnetic resonance imaging: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2022; 59(4): 428–436.
  51. Familiari A, Liberati M, Lim P, et al. Diagnostic accuracy of magnetic resonance imaging in detecting the severity of abnormal invasive placenta: a systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2018; 97(5): 507–520.
  52. Jha P, Pōder L, Bourgioti C, et al. Society of Abdominal Radiology (SAR) and European Society of Urogenital Radiology (ESUR) joint consensus statement for MR imaging of placenta accreta spectrum disorders. Eur Radiol. 2020; 30(5): 2604–2615.
  53. Morel O, Collins SL, Uzan-Augui J, et al. International Society for Abnormally Invasive Placenta (IS-AIP). A proposal for standardized magnetic resonance imaging (MRI) descriptors of abnormally invasive placenta (AIP) - From the International Society for AIP. Diagn Interv Imaging. 2019; 100(6): 319–325.
  54. Einerson BD, Rodriguez CE, Silver RM, et al. Accuracy and Interobserver Reliability of Magnetic Resonance Imaging for Placenta Accreta Spectrum Disorders. Am J Perinatol. 2021; 38(9): 960–967.
  55. Bailit JL, Grobman WA, Rice MM, et al. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Morbidly adherent placenta treatments and outcomes. Obstet Gynecol. 2015; 125(3): 683–689.
  56. Fitzpatrick KE, Sellers S, Spark P, et al. Incidence and risk factors for placenta accreta/increta/percreta in the UK: a national case-control study. PLoS One. 2012; 7(12): e52893.
  57. Silver RM, Fox KA, Barton JR, et al. Center of excellence for placenta accreta. Am J Obstet Gynecol. 2015; 212(5): 561–568.
  58. Levels of Maternal Care: Obstetric Care Consensus No, 9. Obstet Gynecol. 2019; 134(2): e41–e55.
  59. Einerson BD, Healy AJ, Lee A, et al. Society for Maternal-Fetal Medicine (SMFM), SMFM Patient Safety and Quality Committee. Electronic address: smfm@smfm.org. Society for Maternal-Fetal Medicine Special Statement: Emergency checklist, planning worksheet, and system preparedness bundle for placenta accreta spectrum. Am J Obstet Gynecol. 2024; 230(1): B2–BB11.
  60. Sieroszewski P, Bomba-Opon D, Cnota W, et al. Guidelines of the Polish Society of Gynecologists and Obstetricians on the diagnosis and treatment of iron deficiency and iron deficiency with anemia. Ginekol Pol. 2023; 94(5): 415–422.
  61. James AH. Iron Deficiency Anemia in Pregnancy. Obstet Gynecol. 2021; 138(4): 663–674.
  62. Robinson BK, Grobman WA. Effectiveness of timing strategies for delivery of individuals with placenta previa and accreta. Obstet Gynecol. 2010; 116(4): 835–842.
  63. Allen L, Jauniaux E, Hobson S, et al. FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on placenta accreta spectrum disorders: Nonconservative surgical management. Int J Gynaecol Obstet. 2018; 140(3): 281–290.
  64. Mhuircheartaigh NR, C DJ (2022) The National Women and Infants Health Programme (NWIHP) and the Institute of Obstetricians and Gynaecologists (IOG) Clinical Advisory Group (CAG) 2022 {niepełna referencja?}.
  65. Shamshirsaz AA, Fox KA, Salmanian B, et al. Maternal morbidity in patients with morbidly adherent placenta treated with and without a standardized multidisciplinary approach. Am J Obstet Gynecol. 2015; 212(2): 218.e1–218.e9.
  66. Butwick A, Lyell D, Goodnough L. How do I manage severe postpartum hemorrhage? Transfusion. 2020; 60(5): 897–907.
  67. Warrick CM, Rollins MD. Peripartum Anesthesia Considerations for Placenta Accreta. Clin Obstet Gynecol. 2018; 61(4): 808–827.
  68. Warrick CM, Sutton CD, Farber MM, et al. Anesthesia Considerations for Placenta Accreta Spectrum. Am J Perinatol. 2023; 40(9): 980–987.
  69. Viana Pinto P, Kawka-Paciorkowska K, Morlando M, et al. IS‐PAS group. Prevalence of fetal anomalies, stillbirth, neonatal morbidity, or mortality in pregnancies complicated by placenta accreta spectrum disorders. Acta Obstet Gynecol Scand. 2024 [Epub ahead of print].
  70. Bartels HC, Walsh D, Nieto-Calvache AJ, et al. Anesthesia and postpartum pain management for placenta accreta spectrum: The healthcare provider perspective. Int J Gynaecol Obstet. 2024; 164(3): 964–970.
  71. Markley JC, Farber MK, Perlman NC, et al. Neuraxial Anesthesia During Cesarean Delivery for Placenta Previa With Suspected Morbidly Adherent Placenta: A Retrospective Analysis. Anesth Analg. 2018; 127(4): 930–938.
  72. Clark A, Farber M, Sviggum H, et al. Cesarean Delivery in the Hybrid Operating Suite. Anesthesia & Analgesia. 2013; 117(5): 1187–1189.
  73. Einerson BD, Weiniger CF. Placenta accreta spectrum disorder: updates on anesthetic and surgical management strategies. Int J Obstet Anesth. 2021; 46: 102975.
  74. Çetin F, Sucu S, Özcan HÇ, et al. The potential role of preoperative cystoscopy for determining the depth of invasion in the placenta accreta spectrum. Ginekol Pol. 2023 [Epub ahead of print].
  75. Scaglione M, Allshouse A, Canfield D, et al. Prophylactic Ureteral Stent Placement and Urinary Injury During Hysterectomy for Placenta Accreta Spectrum. Obstetrics & Gynecology. 2022; 140(5): 806–811.
  76. Tam Tam KB, Dozier J, Martin JN. Approaches to reduce urinary tract injury during management of placenta accreta, increta, and percreta: a systematic review. J Matern Fetal Neonatal Med. 2012; 25(4): 329–334.
  77. Miller HE, Leonard SA, Fox KA, et al. Placenta Accreta Spectrum Among Women With Twin Gestations. Obstet Gynecol. 2021; 137(1): 132–138.
  78. Khong TY, Robertson WB. Placenta creta and placenta praevia creta. Placenta. 1987; 8(4): 399–409.
  79. Teixidor Viñas M, Chandraharan E, Moneta MV, et al. The role of interventional radiology in reducing haemorrhage and hysterectomy following caesarean section for morbidly adherent placenta. Clin Radiol. 2014; 69(8): e345–e351.
  80. Takahashi H, Ohkuchi A, Usui R, et al. Factors Contributing to Massive Blood Loss on Peripartum Hysterectomy for Abnormally Invasive Placenta: Who Bleeds More? Obstet Gynecol Int. 2016; 2016: 5349063.
  81. Luo F, Xie L, Xie P, et al. Intraoperative aortic balloon occlusion in patients with placenta previa and/or placenta accreta: a retrospective study. Taiwan J Obstet Gynecol. 2017; 56(2): 147–152.
  82. Chou MM, Kung HF, Hwang JI, et al. Temporary prophylactic intravascular balloon occlusion of the common iliac arteries before cesarean hysterectomy for controlling operative blood loss in abnormal placentation. Taiwan J Obstet Gynecol. 2015; 54(5): 493–498.
  83. Pyra K, Szmygin M, Dymara-Konopka W, et al. Maternal and perinatal outcomes in placenta accreta spectrum disorders with prophylactic internal iliac artery balloon catheterization and embolization. Ginekol Pol. 2022; 93(12): 980–986.
  84. Clausen C, Stensballe J, Albrechtsen CK, et al. Balloon occlusion of the internal iliac arteries in the multidisciplinary management of placenta percreta. Acta Obstet Gynecol Scand. 2013; 92(4): 386–391.
  85. Bodner LJ, Nosher JL, Gribbin C, et al. Balloon-assisted occlusion of the internal iliac arteries in patients with placenta accreta/percreta. Cardiovasc Intervent Radiol. 2006; 29(3): 354–361.
  86. Salim R, Chulski A, Romano S, et al. Precesarean Prophylactic Balloon Catheters for Suspected Placenta Accreta: A Randomized Controlled Trial. Obstet Gynecol. 2015; 126(5): 1022–1028.
  87. Sentilhes L, Goffinet F, Kayem G. Management of placenta accreta. Acta Obstet Gynecol Scand. 2013; 92(10): 1125–1134.
  88. Matsueda S, Hidaka N, Kondo Y, et al. External iliac artery thrombosis after common iliac artery balloon occlusion during cesarean hysterectomy for placenta accreta in cervico-isthmic pregnancy. J Obstet Gynaecol Res. 2015; 41(11): 1826–1830.
  89. Bishop S, Butler K, Monaghan S, et al. Multiple complications following the use of prophylactic internal iliac artery balloon catheterisation in a patient with placenta percreta. Int J Obstet Anesth. 2011; 20(1): 70–73.
  90. Gagnon J, Boucher L, Kaufman I, et al. Iliac artery rupture related to balloon insertion for placenta accreta causing maternal hemorrhage and neonatal compromise. Can J Anaesth. 2013; 60(12): 1212–1217.
  91. Teare J, Evans E, Belli A, et al. Sciatic nerve ischaemia after iliac artery occlusion balloon catheter placement for placenta percreta. Int J Obstet Anesth. 2014; 23(2): 178–181.
  92. Greenberg JI, Suliman A, Iranpour P, et al. Prophylactic balloon occlusion of the internal iliac arteries to treat abnormal placentation: a cautionary case. Am J Obstet Gynecol. 2007; 197(5): 470.e1–470.e4.
  93. Sentilhes L, Kayem G, Chandraharan E, et al. FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on placenta accreta spectrum disorders: Conservative management. Int J Gynaecol Obstet. 2018; 140(3): 291–298.
  94. Paping A, Bluth A, Al Naimi A, et al. IS‐PAS. Opportunities for, and barriers to, uterus-preserving surgical techniques for placenta accreta spectrum. Acta Obstet Gynecol Scand. 2024 [Epub ahead of print].
  95. Kwiatkowski S, Huras H, Fuchs T, et al. Rekomendacje Polskiego Towarzystwa Ginekologów i Położników. Postępowania w przypadku wystąpienia krwotoków okołoporodowych. Ginekologia i Perinatologia Praktyczna. 2022; 7: 34–45.
  96. Jolley JA, Nageotte MP, Wing DA, et al. Management of placenta accreta: a survey of Maternal-Fetal Medicine practitioners. J Matern Fetal Neonatal Med. 2012; 25(6): 756–760.
  97. Esakoff TF, Handler SJ, Granados JM, et al. PAMUS: placenta accreta management across the United States. J Matern Fetal Neonatal Med. 2012; 25(6): 761–765.
  98. Jauniaux E, Bhide A. Prenatal ultrasound diagnosis and outcome of placenta previa accreta after cesarean delivery: a systematic review and meta-analysis. Am J Obstet Gynecol. 2017; 217(1): 27–36.
  99. Buyukkurt S, Sucu M, Hatipoglu I, et al. Placenta accreta spectrum surgery with the Joel Cohen incision for abdominal access: a single-center experience. Ginekol Pol. 2023 [Epub ahead of print].
  100. Wright JD, Herzog TJ, Shah M, et al. Regionalization of care for obstetric hemorrhage and its effect on maternal mortality. Obstet Gynecol. 2010; 115(6): 1194–1200.
  101. Sentilhes L, Ambroselli C, Kayem G, et al. Maternal outcome after conservative treatment of placenta accreta. Obstet Gynecol. 2010; 115(3): 526–534.
  102. Timmermans S, van Hof AC, Duvekot JJ. Conservative management of abnormally invasive placentation. Obstet Gynecol Surv. 2007; 62(8): 529–539.
  103. Bręborowicz GH, Markwitz W, Gaca M, et al. Conservative management of placenta previa complicated by abnormal placentation. J Matern Fetal Neonatal Med. 2013; 26(10): 1012–1015.
  104. Pather S, Strockyj S, Richards A, et al. Maternal outcome after conservative management of placenta percreta at caesarean section: a report of three cases and a review of the literature. Aust N Z J Obstet Gynaecol. 2014; 54(1): 84–87.
  105. Clausen C, Lönn L, Langhoff-Roos J. Management of placenta percreta: a review of published cases. Acta Obstet Gynecol Scand. 2014; 93(2): 138–143.
  106. Miyakoshi K, Otani T, Kondoh E, et al. Perinatal Research Network Group in Japan. Retrospective multicenter study of leaving the placenta in situ for patients with placenta previa on a cesarean scar. Int J Gynaecol Obstet. 2018; 140(3): 345–351.
  107. Sentilhes L, Goffinet F, Kayem G. Management of placenta accreta. Acta Obstet Gynecol Scand. 2013; 92(10): 1125–1134.
  108. Zuckerwise LC, Craig AM, Newton JM, et al. Outcomes following a clinical algorithm allowing for delayed hysterectomy in the management of severe placenta accreta spectrum. Am J Obstet Gynecol. 2020; 222(2): 179.e1–179.e9.
  109. Gatta LA, Weber JM, Gilner JB, et al. Transfusion Requirements with Hybrid Management of Placenta Accreta Spectrum Incorporating Targeted Embolization and a Selective Use of Delayed Hysterectomy. Am J Perinatol. 2022; 29(14): 1503–1513.
  110. Chandraharan E, Rao S, Belli AM, et al. The Triple-P procedure as a conservative surgical alternative to peripartum hysterectomy for placenta percreta. Int J Gynaecol Obstet. 2012; 117(2): 191–194.
  111. Aryananda RA, Aditiawarman A, Gumilar KE, et al. Uterine conservative-resective surgery for selected placenta accreta spectrum cases: Surgical-vascular control methods. Acta Obstet Gynecol Scand. 2022; 101(6): 639–648.
  112. Palacios-Jaraquemada JM, Fiorillo A, Hamer J, et al. Placenta accreta spectrum: a hysterectomy can be prevented in almost 80% of cases using a resective-reconstructive technique. J Matern Fetal Neonatal Med. 2022; 35(2): 275–282.
  113. Nieto-Calvache AJ, Palacios-Jaraquemada JM, Aryananda R, et al. How to perform the one-step conservative surgery for placenta accreta spectrum move by move. Am J Obstet Gynecol MFM. 2023; 5(2): 100802.
  114. Clausen C, Lönn L, Langhoff-Roos J. Management of placenta percreta: a review of published cases. Acta Obstet Gynecol Scand. 2014; 93(2): 138–143.
  115. Abo-Elroose AAE, Ahmed MR, Shaaban MM, et al. Triple P with T-shaped lower segment suture; an effective novel alternative to hysterectomy in morbidly adherent anterior placenta previa. J Matern Fetal Neonatal Med. 2021; 34(19): 3187–3191.
  116. Dawood AS, Elgergawy AE, Elhalwagy AE. Evaluation of three-step procedure (Shehata's technique) as a conservative management for placenta accreta at a tertiary care hospital in Egypt. J Gynecol Obstet Hum Reprod. 2019; 48(3): 201–205.
  117. Palacios-Jaraquemada JM, Basanta N, Labrousse C, et al. Pregnancy outcome in women with prior placenta accreta spectrum disorders treated with conservative-reconstructive surgery: analysis of 202 cases. J Matern Fetal Neonatal Med. 2022; 35(25): 6297–6301.
  118. Provansal M, Courbiere B, Agostini A, et al. Fertility and obstetric outcome after conservative management of placenta accreta. Int J Gynaecol Obstet. 2010; 109(2): 147–150.
  119. Sentilhes L, Kayem G, Ambroselli C, et al. Fertility and pregnancy outcomes following conservative treatment for placenta accreta. Hum Reprod. 2010; 25(11): 2803–2810.
  120. Spahn DR, Bouillon B, Cerny V, et al. Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care. 2013; 17(2): R76.
  121. Pacagnella RC, Borovac-Pinheiro A. Assessing and managing hypovolemic shock in puerperal women. Best Pract Res Clin Obstet Gynaecol. 2019; 61: 89–105.
  122. Nolan JP, Pullinger R. Hypovolaemic shock. BMJ. 2014; 348: g1139.
  123. Silva J, Gonçalves L, Sousa PP. Fluid therapy and shock: an integrative literature review. Br J Nurs. 2018; 27(8): 449–454.
  124. McNamara H, Mallaiah S, Barclay P, et al. Coagulopathy and placental abruption: changing management with ROTEM-guided fibrinogen concentrate therapy. Int J Obstet Anesth. 2015; 24(2): 174–179.
  125. Grottke O, Frietsch T, Maas M, et al. German Society of Anaesthesiology and Intensive Care Medicine. [Dealing with massive bleeding and associated perioperative coagulopathy: recommendations for action of the German Society of Anaesthesiology and Intensive Care Medicine]. Anaesthesist. 2013; 62(3): 213–16, 218.
  126. James AH, Kouides PA, Abdul-Kadir R, et al. Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel. Am J Obstet Gynecol. 2009; 201(1): 12.e1–12.e8.
  127. WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017; 389(10084): 2105–2116.
  128. Lavigne-Lissalde G, Aya AG, Mercier FJ, et al. Recombinant human FVIIa for reducing the need for invasive second-line therapies in severe refractory postpartum hemorrhage: a multicenter, randomized, open controlled trial. J Thromb Haemost. 2015; 13(4): 520–529.
  129. Segal S, Shemesh IY, Blumental R, et al. The use of recombinant factor VIIa in severe postpartum hemorrhage. Acta Obstet Gynecol Scand. 2004; 83(8): 771–772.
  130. Yang JI, Lim YK, Kim HS, et al. Sonographic findings of placental lacunae and the prediction of adherent placenta in women with placenta previa totalis and prior Cesarean section. Ultrasound Obstet Gynecol. 2006; 28(2): 178–182.